Medical World Dr Rana Sanjay

🤔 in ?
By🥼🩺 Dr. Rana S. P. Singh, MBBS, MD — Senior Physician, Patna

Hypertension has traditionally been considered an adult disease. However, emerging evidence shows that elevated blood pressure in children and adolescents is increasingly common and frequently underdiagnosed, undertreated, and underestimated. Childhood hypertension is now recognized as an important precursor of adult cardiovascular disease, stroke, and chronic kidney disease.

The Growing Burden of Pediatric Hypertension
Recent global and Indian studies reveal a worrying rise in pediatric hypertension, largely driven by obesity, sedentary lifestyle, excessive screen exposure, unhealthy dietary habits, stress, and poor sleep quality. The prevalence of hypertension among children and adolescents is estimated at approximately 3–5% globally, with even higher rates in overweight and obese children.

Indian school-based studies have reported prevalence figures ranging from 5% to over 20% in some urban populations.
Despite these rising numbers, routine blood pressure screening in children remains inconsistent in many healthcare settings.

🤔Why Is Pediatric Hypertension Often Missed?
👉Several factors contribute to underrecognition:
Blood pressure measurement is not routinely performed in all pediatric visits.
Pediatric BP interpretation is more complex because it depends on age, s*x, and height percentiles rather than fixed adult cutoffs.

Many hypertensive children are asymptomatic.
Lack of awareness among parents and even healthcare providers delays diagnosis.
White coat hypertension and masked hypertension may complicate assessment.

According to current pediatric guidelines, annual BP screening should begin from 3 years of age, and earlier in high-risk children such as those with obesity, renal disease, prematurity, diabetes, or congenital heart disease.

Long-Term Consequences
Persistent hypertension in childhood is not benign. Studies demonstrate early target-organ damage including:
Left ventricular hypertrophy
Vascular stiffness
Retinal changes
Renal injury
Increased lifetime cardiovascular risk
Elevated childhood BP often tracks into adulthood, making early identification crucial.

🤔Is It Undertreated?
👉Yes — evidence strongly suggests that pediatric hypertension remains undertreated worldwide.
Even after diagnosis, many children do not receive structured follow-up, lifestyle counseling, or appropriate pharmacological therapy when indicated. Lifestyle interventions remain the first-line strategy:
Weight reduction
Regular physical activity
Reduced salt intake
Limiting sugary beverages and processed foods
Adequate sleep
Reduced screen time
Pharmacologic treatment is necessary in selected cases, especially when hypertension is severe, symptomatic, secondary, associated with organ damage, or persistent despite lifestyle modification.

The Need for Greater Awareness
Pediatric hypertension should no longer be viewed as rare. Early screening programs in schools and clinics, parental education, and improved physician awareness are essential to prevent future cardiovascular morbidity.
Routine pediatric blood pressure assessment must become as standard as measuring temperature or weight. Detecting hypertension early in life offers an opportunity to alter the trajectory of cardiovascular disease before irreversible damage occurs.
👌Conclusion
Hypertension in children is an emerging public health challenge. Although its prevalence is steadily increasing, diagnosis and treatment remain inadequate in many settings. Greater awareness, early screening, lifestyle intervention, and timely treatment are essential to reduce the long-term burden of cardiovascular and renal disease.
The future of adult cardiovascular health may depend significantly on how effectively we recognize and manage hypertension during childhood today.

✒️🦁Lion DR RANA SANJAY PRATAP SINGH alias Dr. Rana S. P. Singh, MBBS, MD
Senior Physician, Patna

🦁DC 👉 FIRST AID EDUCATION AND EMERGENCY RELIEF⚡ LIONS CLUB INTERNATIONAL DISTRICT 322E

#बिहार

🤔Overlap Between Familial Hyperlipidemia and Atherogenic Diabetic Dyslipidemia: Clinical Approach

✒️🥼🩺By Dr. Rana S. P. Singh
MBBS, MD – Senior Physician & Diabetologist, Patna

👉Introduction
Atherogenic diabetic dyslipidemia and familial hyperlipidemia frequently coexist in clinical practice, especially among patients with type 2 diabetes mellitus (T2DM). This overlap substantially increases the risk of premature atherosclerotic cardiovascular disease (ASCVD), myocardial infarction, stroke, and peripheral vascular disease.
Diabetic dyslipidemia is typically characterized by:
Elevated triglycerides (TG)
Low HDL cholesterol
Small dense LDL particles
Familial hyperlipidemia, especially familial hypercholesterolemia (FH) or familial combined hyperlipidemia (FCHL), is genetically determined and often presents with markedly elevated LDL-C and premature ASCVD.

When both disorders coexist, the lipid abnormalities become more aggressive and difficult to manage.
Pathophysiological Overlap
In diabetic dyslipidemia, insulin resistance leads to:
Increased lipolysis
Excess hepatic VLDL production
Hypertriglyceridemia
Formation of small dense LDL particles
In familial hyperlipidemia, genetic defects impair LDL clearance, leading to persistent LDL accumulation.

The coexistence of these mechanisms creates:
Severe mixed dyslipidemia
Accelerated endothelial dysfunction
Heightened inflammatory response
Rapid progression of atherosclerosis
Clinical Clues Suggesting Overlap
The possibility of familial dyslipidemia should be suspected in diabetic patients with:
LDL-C persistently >190 mg/dL
Strong family history of premature CAD
Tendon xanthomas or corneal arcus
Mixed hyperlipidemia despite glycemic control
Premature ASCVD at young age
Very high ApoB or non-HDL cholesterol
Familial combined hyperlipidemia is particularly common and may mimic diabetic dyslipidemia.

Diagnostic Approach
1. Complete Lipid Profiling
Recommended investigations include:
Total cholesterol
LDL-C
HDL-C
Triglycerides
Non-HDL cholesterol
ApoB
Lipoprotein(a)
2. Family Screening
Cascade screening among first-degree relatives is essential in suspected familial disorders.
3. Evaluate Secondary Factors
Assess for:
Poor glycemic control
Hypothyroidism
Nephrotic syndrome
Obesity
Alcohol excess
Drug-induced dyslipidemia
Therapeutic Approach
1. Lifestyle Intervention
Lifestyle modification remains foundational:
Mediterranean or DASH diet
Reduction in saturated and trans fats
Weight reduction
Regular aerobic exercise
Smoking cessation
Even modest weight reduction improves insulin resistance and lipid abnormalities.

2. Aggressive Glycemic Control
Improved glycemic control reduces:
Hepatic VLDL synthesis
Triglycerides
Small dense LDL formation
Agents with cardiometabolic benefits include:
SGLT2 inhibitors
GLP-1 receptor agonists
3. Statin Therapy: Cornerstone Treatment
LDL reduction remains the primary target.
Most patients with overlap syndrome require:
High-intensity statins
≥50% LDL-C reduction
Examples:
Atorvastatin 40–80 mg
Rosuvastatin 20–40 mg
Current guidelines recommend intensive lipid lowering in diabetic patients with familial dyslipidemia due to extremely high ASCVD risk.

4. Combination Lipid-Lowering Therapy
If LDL goals are not achieved:
Add ezetimibe
Consider PCSK9 inhibitors in very high-risk individuals
For persistent hypertriglyceridemia:
Fenofibrate
Icosapent ethyl (EPA)
Combination therapy may be necessary in mixed dyslipidemia.

5. Treatment Targets
Modern recommendations favor:
LDL-C